Vanda Pharmaceuticals Inc
NASDAQ:VNDA
Vanda Pharmaceuticals Inc
NASDAQ:VNDA
Price:
4.82 USD
4.33%
Market Closed
Updated:
Apr 30, 2024
Vanda Pharmaceuticals Inc
Net Income (Common)
|
Vanda Pharmaceuticals Inc
Net Income (Common) Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Vanda Pharmaceuticals Inc
NASDAQ:VNDA
|
Net Income (Common)
$2.5m
|
CAGR 3-Years
-52%
|
CAGR 5-Years
-37%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Net Income (Common)
$4.8B
|
CAGR 3-Years
2%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
2%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Net Income (Common)
$5.7B
|
CAGR 3-Years
258%
|
CAGR 5-Years
1%
|
CAGR 10-Years
6%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Net Income (Common)
$6.7B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
3%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Net Income (Common)
$3.6B
|
CAGR 3-Years
10%
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Net Income (Common)
$4B
|
CAGR 3-Years
4%
|
CAGR 5-Years
10%
|
CAGR 10-Years
25%
|
See Also
What is Vanda Pharmaceuticals Inc's Net Income (Common)?
Net Income (Common)
2.5m
USD
2.5m
USD
Based on the financial report for Dec 31, 2023, Vanda Pharmaceuticals Inc's Net Income (Common) amounts to 2.5m USD.
What is Vanda Pharmaceuticals Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
-37%
-37%
Over the last year, the Net Income (Common) growth was -60%. The average annual Net Income (Common) growth rates for Vanda Pharmaceuticals Inc have been -52% over the past three years , -37% over the past five years .
You don't have any saved screeners yet
